ID: ALA4285374

Max Phase: Preclinical

Molecular Formula: C18H16N6O3

Molecular Weight: 364.37

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CCOC(=O)c1cnc(NNc2ccccc2)n2nc(-c3ccco3)nc12

Standard InChI:  InChI=1S/C18H16N6O3/c1-2-26-17(25)13-11-19-18(22-21-12-7-4-3-5-8-12)24-16(13)20-15(23-24)14-9-6-10-27-14/h3-11,21H,2H2,1H3,(H,19,22)

Standard InChI Key:  HNBPNETVLFXBCZ-UHFFFAOYSA-N

Associated Targets(Human)

Adenosine A1 receptor 17603 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Adenosine A2a receptor 16305 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Adenosine A2b receptor 7672 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Adenosine A3 receptor 15931 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Adenosine receptors; A1 & A3 1051 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 364.37Molecular Weight (Monoisotopic): 364.1284AlogP: 3.00#Rotatable Bonds: 6
Polar Surface Area: 106.58Molecular Species: NEUTRALHBA: 9HBD: 2
#RO5 Violations: 0HBA (Lipinski): 9HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: CX LogP: 4.11CX LogD: 4.11
Aromatic Rings: 4Heavy Atoms: 27QED Weighted: 0.40Np Likeness Score: -1.87

References

1. Federico S, Margiotta E, Salmaso V, Pastorin G, Kachler S, Klotz KN, Moro S, Spalluto G..  (2018)  [1,2,4]Triazolo[1,5-c]pyrimidines as adenosine receptor antagonists: Modifications at the 8 position to reach selectivity towards A3 adenosine receptor subtype.,  157  [PMID:30144700] [10.1016/j.ejmech.2018.08.042]

Source